Cytokinetics CYTK Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's additional paid-in capital?
- Cytokinetics (CYTK) reported additional paid-in capital of $2.87B in Q1 2026.
- How has Cytokinetics's additional paid-in capital changed year-over-year?
- Cytokinetics's additional paid-in capital increased by 10.5% year-over-year, from $2.6B to $2.87B.
- What is the long-term trend for Cytokinetics's additional paid-in capital?
- Over 5 years (2020 to 2025), Cytokinetics's additional paid-in capital has grown at a 20.7% compound annual growth rate (CAGR), from $1.11B to $2.83B.
- What does additional paid-in capital mean?
- The surplus capital contributed by investors above the nominal par value of shares.
- How do you interpret additional paid-in capital?
- Growth in this account indicates successful equity financing rounds or the exercise of stock options by employees.
- How does additional paid-in capital compare across companies?
- High levels are common in growth-stage biotechs that have raised significant capital from public markets.